ArticleResearch (Washington, D.C.)2025
Microfluidic Perfusable Pathological Vasculature for Atherosclerosis Drug Screening.
Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Smooth muscle cell spheroids as 3D model of phenotypic plasticity and matrix deposition revealed by 2D-3D proteomics.Scientific reports · 2026Article
- Microfluidic Chip Platforms for Red Blood Cell Storage Lesion Quality Control and Precision Transfusion.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current in vitro atherosclerosis (AS) models struggle to stimulate blood flow, limiting their ability to replicate endothelial injury and drug transport in AS development. To address this, we developed a 3-dimensional perfusable atherosclerotic vessel-on-a-chip (3D-PAVoC) platform that mimics vascular structure, blood circulating, and disease microenvironment. The system integrates endothelial cells and smooth muscle cells within a flow-enabled arterial construct, exposed to inflammatory (tumor necrosis factor-α and interleukin-1β) and hyperlipidemic stimuli (oxidized low-density lipoprotein) to recreate AS-prone conditions. Flow-dependent endothelial responses including enhanced cell growth and survival were observed, confirming the importance of hemodynamics in disease modeling. Then, rapamycin (RAP) was used as a model drug to evaluate therapeutic effects in the 3D-PAVoC. Compared to static vessel-on-a-chip models and conventional 2-dimensional cultures, 3D-PAVoC exhibited more pronounced AS pathology and higher RAP half-maximal inhibitory concentration, better reflecting in vivo conditions. The effective RAP dose identified in vitro was validated in apolipoprotein E knockout (ApoE
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.